NICE Recommends BioCryst's ORLADEYO® (berotralstat), the First Oral, Once-daily Therapy, to Prevent Attacks in HAE Patients in the UKGlobeNewsWire • 09/16/21
U.S. Government Exercises Option to Purchase Additional RAPIVAB® (peramivir injection) from BioCryst for Delivery to Strategic National StockpileGlobeNewsWire • 09/01/21
BioCryst Announces Acceptance of Regulatory Applications for ORLADEYO® (berotralstat) by Health Canada and SwissmedicGlobeNewsWire • 08/25/21
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/05/21
Tuesday Afternoon Analyst Upgrades and Downgrades: Exxon Mobil, First Solar, Tesla and More24/7 Wall Street • 08/03/21
BioCryst Announces Designs for REDEEM-1 and REDEEM-2 Pivotal Trials with BCX9930 as Oral Monotherapy for Patients with PNHGlobeNewsWire • 07/15/21
BioCryst Reports 96-week Data from APeX-2 Showing ORLADEYO®(berotralstat) Reduced HAE Attack Rate by 80 Percent from BaselineGlobeNewsWire • 07/10/21